Cargando...
Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy
Irritable bowel syndrome (IBS) is the most common gastrointestinal (GI) disorder worldwide, however treatment options for diarrhea-predominant IBS (IBS-D) remain limited. Eluxadoline, a µ- and κ-opioid receptor agonist and δ-opioid receptor antagonist, was recently approved for the treatment of IBS-...
Gardado en:
| Publicado en: | Ther Adv Chronic Dis |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publications
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5638229/ https://ncbi.nlm.nih.gov/pubmed/29090081 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622317714389 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|